Payment overview · 2025
General Payments
$1,044.33
43 reported records · 22 companies
Healthcare provider profile · identity verified
Maya Lucas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARIETTA, GA · NPI 1912490996
Verified facts
What the public records show
CMS Open Payments records show Maya Lucas, MD received $1,044.33 in general payments during 2025 across 43 reported records.
UCB, Inc. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $188.26 | 18.0% | 6 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $102.25 | 9.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $96.53 | 9.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.47 | 6.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.34 | 6.6% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $63.01 | 6.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $53.17 | 5.1% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $46.00 | 4.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.23 | 4.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.05 | 3.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.29 | 3.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.29 | 2.9% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $26.05 | 2.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.80 | 2.4% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$22.97 | 2.2% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $22.00 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.63 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.26 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.68 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.72 | 1.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.90 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.43 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,044.33 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $112.78 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $96.53 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $75.48 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $69.34 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $63.01 | 2 | 2025 |
Source payment records
|
|||||
| Evrysdi Normalized: evrysdi |
Drug | Genentech USA, Inc. | $46.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.59 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.59 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.05 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 120 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
120 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 675 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 116 |
| Losartan Potassium | Losartan Potassium | 294 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 91 |
| Lisinopril | Lisinopril | 234 | 81 |
| Metformin Hcl | Metformin Hcl | 225 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 211 | 51 |
| Ozempic | Semaglutide | 164 | 33 |
| Alprazolam | Alprazolam | 153 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 43 |
| Omeprazole | Omeprazole | 138 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 45 |
| Simvastatin | Simvastatin | 126 | 39 |
| Gabapentin | Gabapentin | 124 | 45 |
| Mounjaro | Tirzepatide | 120 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 35 |
| Trazodone Hcl | Trazodone Hcl | 95 | 40 |
| Alendronate Sodium | Alendronate Sodium | 86 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 27 |
| Sertraline Hcl | Sertraline Hcl | 70 | 23 |
| Valacyclovir | Valacyclovir Hcl | 69 | 23 |
| Lorazepam | Lorazepam | 66 | 21 |
| Atenolol | Atenolol | 60 | 18 |
| Bupropion Xl | Bupropion Hcl | 59 | 21 |
| Ezetimibe | Ezetimibe | 58 | 28 |
| Montelukast Sodium | Montelukast Sodium | 58 | 23 |
| Descovy | Emtricitabine/Tenofov Alafenam | 57 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 24 |
| Carvedilol | Carvedilol | 56 | 22 |
| Clonazepam | Clonazepam | 55 | 15 |
| Eliquis | Apixaban | 55 | 20 |
| Jardiance | Empagliflozin | 54 | 16 |
| Allopurinol | Allopurinol | 52 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 17 |
| Glimepiride | Glimepiride | 47 | 18 |
| Furosemide | Furosemide | 46 | 21 |
| Meloxicam | Meloxicam | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Irbesartan | Irbesartan | 43 | 18 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 39 | suppressed |
| Valsartan | Valsartan | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 20 |
| Famotidine | Famotidine | 37 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | 13 |
| Anastrozole | Anastrozole | 31 | 14 |
| Testosterone | Testosterone | 31 | suppressed |
| Finasteride | Finasteride | 30 | 13 |
| Azithromycin | Azithromycin | 29 | 27 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 24 |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | 11 |
| Ramipril | Ramipril | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 13 |
| Prednisone | Prednisone | 20 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Temazepam | Temazepam | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tivicay | Dolutegravir Sodium | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | 11 |
| Trulicity | Dulaglutide | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,044.33 · 43 records | UCB, Inc. | APRETUDE, Bimzelx, CREXONT, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, Evrysdi, FREESTYLE LIBRE 3, LEQEMBI, LEQVIO, MOUNJARO, NUPLAZID, Ozempic, PONVORY, QULIPTA, REZDIFFRA, Rybelsus, Rystiggo, Symbravo, UBRELVY, UNITHROID, VALTOCO, VYEPTI, Veozah, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error